Serum Lipid Level in Evaluating Chinese Pancreatic Neuroendocrine Neoplasms: A Retrospective Study
Experimental and Clinical Endocrinology & Diabetes · 01.02.2024 · 132 (02) · 98-106
DOI: 10.1055/a-2229-3489 ↗Kurz gefasst
Fachartikel in der Zeitschrift Experimental and Clinical Endocrinology & Diabetes, erschienen am 01.02.2024. Verfasst von Danyang Gu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Geriatric Gastroenterology, Neuroendocrine Tumor Center, Jiangsu Province Hospital, The First Affiliated Hospital of Nanjing Medical Un…. Hauptthemen laut MEDLINE: Neuroendocrine Tumors, Pancreatic Neoplasms, Dyslipidemias. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: New Clinical TreatmentTechnology Research Fund, Wuxi "Taihu talent plan" for the excellent medical expert team, National Natural Science Foundation of China.
Abstract (Originalsprache)
Background
Pancreatic neuroendocrine neoplasms (p-NENs) are relatively rare and highly heterogeneous. Dyslipidemia may be related to the risk of developing p-NENs, although dyslipidemia in patients with p-NENs is rarely reported. In this study, the clinical characteristics of p-NENs patients with different lipid levels and their prognostic value in p-NENs patients were evaluated.
Methods
Patients (n=211) with p-NENs hospitalized at Jiangsu Neuroendocrine Tumor Centre of Jiangsu Province Hospital from December 2018 to December 2022 were enrolled. Clinical data related to p-NENs were collected. Based on the EGA database, the related lipoprotein, low-density lipoprotein receptor (LDLR) and high-density lipoprotein binding protein (HDLBP) mRNA in p-NENs and paratumoral tissues and the follow-up information of p-NENs were evaluated.
Results
A total of 175 p-NENs patients ultimately met the inclusion criteria. The ki67 index was higher in p-NENs patients with elevated lipid with the proportion of≥5, and in those with AJCC stage III and stage IV than p-NENs patients with low-level lipid. In p-NENs patients, the expression of HDLBP mRNA was downregulated in p-NENs tissues compared to the paratumoral tissues. Survival analysis showed that serum lipids had no effect on the prognosis of p-NENs; however, high LDLR level p-NENs were at the risk of poor survival.
Conclusion
Serum lipid level in p-NENs can affect the grading and staging, but the correlation with the prognosis of p-NENs is not significant. However, dyslipidemia may be a potential predictor of p-NENs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Geriatric Gastroenterology, Neuroendocrine Tumor Center, Jiangsu Province Hospital, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
- Department of Microbiology, Nanjing Medical University, Nanjing, China.
Förderung
- New Clinical TreatmentTechnology Research Fund
- Wuxi "Taihu talent plan" for the excellent medical expert team
- National Natural Science Foundation of China
- Science Foundation Project of Ili & Jiangsu Joint Institute of Health
Zitieren
APA
Gu, D., Xue, B., Zhu, G., Xu, Y., Yan, L., Tang, Q., & Lu, C. (2024). Serum Lipid Level in Evaluating Chinese Pancreatic Neuroendocrine Neoplasms: A Retrospective Study. Experimental and Clinical Endocrinology & Diabetes, 132(02), 98-106. https://doi.org/10.1055/a-2229-3489
Vancouver
Gu D, Xue B, Zhu G, Xu Y, Yan L, Tang Q, et al. Serum Lipid Level in Evaluating Chinese Pancreatic Neuroendocrine Neoplasms: A Retrospective Study. Experimental and Clinical Endocrinology & Diabetes. 2024;132(02):98-106. doi:10.1055/a-2229-3489
BibTeX
@article{Gu2024,
author = {Gu, Danyang and Xue, Bingyan and Zhu, Guoqin and Xu, Yanling and Yan, Lijun and Tang, Qiyun and Lu, Chun},
title = {Serum Lipid Level in Evaluating Chinese Pancreatic Neuroendocrine Neoplasms: A Retrospective Study},
journal = {Experimental and Clinical Endocrinology & Diabetes},
year = {2024},
volume = {132},
number = {02},
pages = {98--106},
doi = {10.1055/a-2229-3489}
}
EUVIMED